نتایج جستجو برای: 004

تعداد نتایج: 6002  

2011
Kathrin Kiok Hong Sun Hailey Clancy Sutapa Bose Thomas Kluz Fen Wu Max Costa

Liprin-α4 was strongly induced following nickel (II) chloride exposure in a variety of cell types including BEAS-2B, A549, BEP2D and BL41 cells. Liprin-α4, a member of the Liprin alpha family, has seven isoforms but only three of these variants were detected in BEAS-2B cells (004, 201 and 202). The level of Liprin-α4 variants 201 and 004 were highly increased in BEAS-2B cells in response to nic...

2016
Sara E.S. Lange Alex Zheleznyak Matthew Studer Daniel J. O'Shannessy Suzanne E. Lapi Brian A. Van Tine

PURPOSE The complexity of sarcoma has led to the need for patient selection via in vivo biomarkers. Tumor endothelial marker-1 (TEM-1) is a cell surface marker expressed by the tumor microenvironment. Currently MORAb-004 (Ontuxizumab), an anti-TEM-1 humanized monoclonal antibody, is in sarcoma clinical trials. Development of positron emission tomography (PET) for in vivo TEM-1 expression may al...

2015
Lilia Weiss Dianna Gary Arlene S Swern John Freeman Mary M Sugrue

BACKGROUND Lenalidomide is approved for treating transfusion-dependent anemia due to lower-risk del(5q) myelodysplastic syndromes (MDS). In clinical trials, rash was common, although severe rash was infrequent. To examine rash in patients with MDS treated with lenalidomide in the real world, the Celgene Global Drug Safety database was analyzed and compared with clinical trials. MATERIALS AND ...

2008
Klaus Richter Pierre Lugan Philippe Bouyer Gora Shlyapnikov Laurent Sanchez-Palencia Axel Pelster Robert Graham John Schofield Tsutomu Momoi Philippe Sindzingre

DY 1.1 Mon 10:00–10:30 MA 004 The Thermodynamic Casimir Effect: Monte Carlo Results — •Alfred Hucht DY 2.9 Mon 12:30–13:00 MA 001 New Results on Water in Bulk, Nanoconfined, and Biological Environments — •H. Eugene Stanley DY 4.1 Mon 14:00–14:30 MA 004 Entropic particle transport — •Gerhard Schmid, P. Sekhar Burada, Peter Hänggi DY 11.1 Tue 9:30–10:00 EB 407 Glass freezing in confined geometrie...

2012
Derrick W. Crook A. Sarah Walker Yin Kean Karl Weiss Oliver A. Cornely Mark A. Miller Roberto Esposito Thomas J. Louie Nicole E. Stoesser Bernadette C. Young Brian J. Angus Sherwood L. Gorbach Timothy E. A. Peto

Two recently completed phase 3 trials (003 and 004) showed fidaxomicin to be noninferior to vancomycin for curing Clostridium difficile infection (CDI) and superior for reducing CDI recurrences. In both studies, adults with active CDI were randomized to receive blinded fidaxomicin 200 mg twice daily or vancomycin 125 mg 4 times a day for 10 days. Post hoc exploratory intent-to-treat (ITT) time-...

Journal: :International Journal of Infectious Diseases 2011

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید